Sylvie Ryckebusch
Corporate Officer/Principal at BIOINVENT INTERNATIONAL AB
Net worth: 28 411 $ as of 2024-03-30
Profile
Sylvie Ryckebusch currently works at Domain Therapeutics SA, as Non-Executive Director and BioInvent International AB, as Chief Business Officer from 2022.
Dr. Ryckebusch received her doctorate degree from California Institute of Technology and undergraduate degree from the University of Maryland.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2022-12-30 | 17,870 ( 0.03% ) | 28 411 $ | 2024-03-30 |
Sylvie Ryckebusch active positions
| Companies | Position | Start |
|---|---|---|
| BIOINVENT INTERNATIONAL AB | Corporate Officer/Principal | 2022-06-08 |
Domain Therapeutics SA
 Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Director/Board Member | - |
Training of Sylvie Ryckebusch
| California Institute of Technology | Doctorate Degree |
| University of Maryland | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BIOINVENT INTERNATIONAL AB | Health Technology |
| Private companies | 1 |
|---|---|
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
- Stock Market
- Insiders
- Sylvie Ryckebusch
